The Therapeutic Surrogate and Predictive Markers in the Treatment for MALT Lymphoma from the Viewpoint of Molecular Genetics Toshihiko Doi 1 , Hisashi Endo 1 , Shouji Hirasaki 1 , Tomohiro Nishina 1 1Department of Internal Medicine, National Shikoku Cancer Center Hospital Keyword: MALTリンパ腫 , 分子生物学的マーカー , 遺伝子診断 pp.575-582
Published Date 2002/3/25
DOI https://doi.org/10.11477/mf.1403103495
  • Abstract
  • Look Inside

 The t (11;18) (q21;q21) chromosome translocation, which results in the synthesis of a fusion gene and protein “chimeric API2-MLT” has been used for a new approach to the evaluation of gastric MALT lymphomas. It is only suggested that the phenotypes with this chimeric gene respond poorly to H. pylori eradication treatment, but do not indicate the risk of transformation and overall prognosis. We detected several molecular markers (chromosome abnormalities, apoptosis markers, oncogenes, telomerase associated genes etc) in gastric lymphoma patients in the early clinical stage. The lymphoma patients were divided into two group according to the patterns of positive markers. One group includes the patients with chromosomal abnormality (translocation, deletion, trisomy etc) (CAG: chromosome abnormal group). The other group consists of only the patients with abnormalities in non-specific markers (the associated gene and protein of apoptosis and/or telomerase, oncogene, tumor suppressor gene etc) and without chromosomal disorders (NCAG: non chromosome abnormal group). The patients in the former group (CAG) show poor response and are resistant to the treatment for H. pylori eradication. The patients in the latter group with a few abnormalities of non-specific molecular markers show a good response and improvement after H. pylori eradication treatment, but the patients with many abnormalities of molecular markers show resistance to therapy or rapid progression of lymphoma. Considering these facts, the pre-detection of molecular abnormalities is expected to be a good surrogate marker for predicting the response in eradication therapy or other treatment.

Copyright © 2002, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院